ImPassion130 Study Outcomes

ImPassion130 Study Outcomes

obr

4 months
30 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of Medicine, Harvard Medical School shares the results of ImPassion130 study, a phase III adding atezolizumab to the 1st line chemotherapy with nab-paclitaxel in patients with PD-L1 positive metastatic triple-negative cancer (TNBC).
Up Next Autoplay
Landscape of Metastatic Hormone-Sensitive Prostate Cancer
Landscape of Metastatic Hormone-Sensitive Prostate Cancer
Category: Kidney Cancer
1,151 Views
obr 4 months
Most Anticipated Trial Results Regarding Biomarkers in RCC
Most Anticipated Trial Results Regarding Biomarkers in RCC
Category: Kidney Cancer
416 Views
obr 4 months
Strategies for Treating RCC in the 2nd Line Setting
Strategies for Treating RCC in the 2nd Line Setting
Category: Kidney Cancer
270 Views
obr 4 months
Perspective on Treating Newly Diagnosed RCC Patients
Perspective on Treating Newly Diagnosed RCC Patients
Category: Kidney Cancer
286 Views
obr 4 months
Studies in Sarcomatoid RCC and Urothelial Cancer
Studies in Sarcomatoid RCC and Urothelial Cancer
Category: Kidney Cancer
220 Views
obr 4 months
PDIGREE Trial in Metastatic Untreated RCC
PDIGREE Trial in Metastatic Untreated RCC
Category: Kidney Cancer
130 Views
obr 4 months
Smoldering MM Presented at ASCO 2019
Smoldering MM Presented at ASCO 2019
Category: Multiple Myeloma
179 Views
obr 4 months
MAIA Study Outcomes
MAIA Study Outcomes
Category: Multiple Myeloma
276 Views
obr 4 months
IV Daratumumab versus Subcutaneous Daratumumab
IV Daratumumab versus Subcutaneous Daratumumab
Category: Acute Lymphoblastic Leukemia
114 Views
obr 4 months
SOPHIA Trial in HER+ Metastatic Breast Cancer
SOPHIA Trial in HER+ Metastatic Breast Cancer
Category: Acute Lymphoblastic Leukemia
136 Views
obr 4 months